129 related articles for article (PubMed ID: 3863621)
1. [Effect of the molecular structure of anthracycline compounds on their intercalation into DNA].
Brikenshteĭn VKh; Baranov EP; Pitina LR; Bushelev SN
Bioorg Khim; 1985 Jul; 11(7):934-43. PubMed ID: 3863621
[TBL] [Abstract][Full Text] [Related]
2. [Genotoxic and mutagenic activity of antineoplastic anthracyclines and their aglycones: study in two test-systems].
Vasil'eva SV; Makhova EV; Efremenkova OV; Bartoshevich IuE
Genetika; 1996 Feb; 32(2):233-9. PubMed ID: 8713623
[TBL] [Abstract][Full Text] [Related]
3. Sequence specificity, enantiospecificity and polyelectrolyte effect in the binding to DNA of a 6-(2-pyridyl)phenanthridine chiral photonuclease.
Colmenarejo G; Montero F; Orellana G
Anticancer Drug Des; 1997 Jun; 12(4):239-60. PubMed ID: 9199658
[TBL] [Abstract][Full Text] [Related]
4. [Oxidation of anthracycline antibiotics].
Orlov VS; Bogdanov GN
Antibiotiki; 1984 Oct; 29(10):748-51. PubMed ID: 6594969
[TBL] [Abstract][Full Text] [Related]
5. Interaction of anthracycline antibiotics with biopolymers: comparative studies of DNA binding and antimicrobial activity of rhodomycin-type anthracycline antibiotics.
Stutter E; Walter A; Fleck WF
J Basic Microbiol; 1986; 26(10):607-20. PubMed ID: 3108489
[TBL] [Abstract][Full Text] [Related]
6. Kinetic and equilibrium studies of the interaction of amsacrine and anilino ring-substituted analogues with DNA.
Denny WA; Wakelin LP
Cancer Res; 1986 Apr; 46(4 Pt 1):1717-21. PubMed ID: 3753896
[TBL] [Abstract][Full Text] [Related]
7. Interaction of bisantrene anti-cancer agents with DNA: footprinting, structural requirements for DNA unwinding, kinetics and mechanism of binding and correlation of structural and kinetic parameters with anti-cancer activity.
Elliott JA; Wilson WD; Shea RG; Hartley JA; Reszka K; Lown JW
Anticancer Drug Des; 1989 Mar; 3(4):271-82. PubMed ID: 2539168
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization.
Hartley JA; Reszka K; Zuo ET; Wilson WD; Morgan AR; Lown JW
Mol Pharmacol; 1988 Mar; 33(3):265-71. PubMed ID: 3352592
[TBL] [Abstract][Full Text] [Related]
9. Molecular modelling of DNA-antitumour drug intercalation interactions: correlation of structural and energetic features with biological properties for a series of phenylquinoline-8-carboxamide compounds.
McKenna R; Beveridge AJ; Jenkins TC; Neidle S; Denny WA
Mol Pharmacol; 1989 May; 35(5):720-8. PubMed ID: 2725476
[TBL] [Abstract][Full Text] [Related]
10. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic.
Leng F; Priebe W; Chaires JB
Biochemistry; 1998 Feb; 37(7):1743-53. PubMed ID: 9485299
[TBL] [Abstract][Full Text] [Related]
11. Studies of anthracycline--DNA complexes by circular dichroism.
Rizzo V; Penco S; Menozzi M; Geroni C; Vigevani A; Arcamone F
Anticancer Drug Des; 1988 Aug; 3(2):103-15. PubMed ID: 3165639
[TBL] [Abstract][Full Text] [Related]
12. Electrostatic and non-electrostatic contributions to the binding free energies of anthracycline antibiotics to DNA.
Baginski M; Fogolari F; Briggs JM
J Mol Biol; 1997 Nov; 274(2):253-67. PubMed ID: 9398531
[TBL] [Abstract][Full Text] [Related]
13. Association of anthracycline derivatives with DNA: a fluorescence study.
Valentini L; Nicolella V; Vannini E; Menozzi M; Penco S; Arcamone F
Farmaco Sci; 1985 Jun; 40(6):377-90. PubMed ID: 3861331
[TBL] [Abstract][Full Text] [Related]
14. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of a new bisintercalating anthracycline antibiotic.
Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
[TBL] [Abstract][Full Text] [Related]
16. Binding of the antitumor drug nogalamycin to bulged DNA structures.
Caceres-Cortes J; Wang AH
Biochemistry; 1996 Jan; 35(2):616-25. PubMed ID: 8555235
[TBL] [Abstract][Full Text] [Related]
17. A non-classical intercalation model for a bleomycin amplifier.
Strekowski L; Wilson WD; Mokrosz JL; Strekowska A; Koziol AE; Palenik GJ
Anticancer Drug Des; 1988 Mar; 2(4):387-98. PubMed ID: 2452646
[TBL] [Abstract][Full Text] [Related]
18. A theoretical study of the intercalative binding of the anti-tumour drug anthrapyrazole to double-stranded oligonucleotides.
Chen KX; Gresh N; Pullman B
Anticancer Drug Des; 1987 Aug; 2(1):79-84. PubMed ID: 3482353
[TBL] [Abstract][Full Text] [Related]
19. Sequence specificity in the binding of anti-tumour anthracyclines to DNA: a success of theory.
Pullman B
Anticancer Drug Des; 1991 May; 6(2):95-105. PubMed ID: 2039585
[TBL] [Abstract][Full Text] [Related]
20. Study on the interaction of morphine chloride with deoxyribonucleic acid by fluorescence method.
Li JF; Dong C
Spectrochim Acta A Mol Biomol Spectrosc; 2009 Jan; 71(5):1938-43. PubMed ID: 18818119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
